While children undergoing immunosuppressive treatment for cancer are known to have a high risk for invasive pneumococcal disease, few studies have examined the safety and efficacy of the PCV13 in this...
In 2014, The Advisory Committee on Immunization Practices recommended the routine use of 13-valent pneumococcal conjugate vaccine among adults 65 years of age or older, and for it to be administered with...
